Why the study?
Do patients with acute leukaemia and lymphoma have left ventricular dysfunction prior to and following chemotherapy?
Do patients with acute leukaemia and lymphoma have left ventricular dysfunction prior to and following chemotherapy?
A significant proportion of patients with acute leukaemia and lymphoma exhibit non-infiltrative left ventricular dysfunction even before receiving cardiotoxic chemotherapy.
Answers are grounded in this paper and cite their sources.
Pre-treatment LV assessment may be considered in leukaemia-lymphoma; this Level 3 evidence leaves open disease-related mechanisms and requires prospective confirmation.
Left ventricular function was assessed with echocardiography in 27 normal subjects and in 38 patients with acute leukaemia and lymphoma. Eighteen patients in the leukaemia-lymphoma group (47%) had left ventricular dysfunction before chemotherapy as suggested by a significantly (P < 0.001) abnormal end-systolic dimension and a low fractional shortening. Cardiac failure developed in 12 patients (32%): 3 patients with preleukaemia, 3 with acute myeloid leukaemia, and 1 with Hodgkin's disease had heart failure before cytotoxic therapy and 5 others developed it within 3 to 24 weeks after 75 to 920 mg daunorubicin. Cardiac failure in 5 of the 7 pre-daunorubicin cases was well controlled while all the 5 patients who developed left ventricular failure after daunorubicin died. In 3 of these the heart failure was the only cause of death. Necropsy in 4 patients showed no leukaenmic infiltration ofthe myocardium. Sequential echocardiograms showed a deterioration in left ventricular function during the first 6 months and a steady improvement in patients who lived longer than 9 months.
No takes yet. Share an insight, caveat, or question.
Mariam Mir (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: